Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Novartis took a $1.9 billion writedown following a drug trial failure involving del-desiran after its Avidity acquisition, alongside a broader $2.2 billion hit from drug trial setbacks. Despite these financial impacts on profit, the CEO maintained confidence in the acquisition and long-term revenue goals.
Consequently, the company raised its annual profit guidance.
Epilogue added 16d ago, after coverage quieted.
The brief
Recent business reporting details a significant financial and clinical development involving pharmaceutical company Novartis. According to coverage from outlets including BioSpace, the Wall Street Journal, Fierce Pharma, the Financial Times, FirstWord Pharma, Reuters, and Fierce Biotech, Novartis is managing a $1.9 billion hit tied to the failure of the drug del-desiran. Additional reporting from Reuters notes a broader total financial impact of $2.2 billion stemming from various drug trial setbacks. Despite these substantial write-downs and trial failures, the leadership at Novartis has expressed continued confidence in its broader corporate strategy, specifically maintaining faith in a twelve billion dollar acquisition involving Avidity. Media coverage heavily emphasizes the resilience of the company's executive leadership in the face of these high-profile clinical failures.
The Financial Times and Fierce Pharma highlight that the chief executive officer remains unfazed by the setbacks, keeping long-term revenue goals intact. Simultaneously, financial reporting from the Wall Street Journal, FirstWord Pharma, and Reuters points out that Novartis has chosen to raise its annual profit guidance. This juxtaposition of substantial drug trial writedowns alongside lifted financial guidance forms the primary focus of the business reporting across all seven tracked news sources. This unfolding situation builds upon prior corporate actions and major financial investments by Novartis, most notably the blockbusting twelve billion dollar acquisition of Avidity. The recent clinical failure of del-desiran represents a major hurdle following that acquisition, testing the pharmaceutical firm's broader pipeline and financial resilience.
Coverage does not yet specify the exact operational steps researchers will take next regarding the failed drug, but the current reporting establishes that the company's long-term financial planning remains anchored despite the immediate losses. Observers and market analysts will be tracking subsequent corporate announcements to monitor how Novartis navigates its updated profit guidance and integrates its major acquisitions following these trials. While current headlines establish the immediate financial hits and leadership responses, future coverage will likely determine the longer-term market repercussions of the del-desiran setback. Readers should consult ongoing financial reports for updates on how the company manages its remaining portfolio in light of these multi-billion dollar adjustments.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 18d ago.
Quick answers
What caused the financial hit for Novartis?
Coverage states the hit stems from drug trial setbacks, specifically including a failure of the drug del-desiran.
Did the financial losses alter Novartis's profit expectations?
No, according to coverage, Novartis actually raised its annual profit guidance despite the setbacks.
How does leadership view the Avidity acquisition following the trial failure?
Coverage indicates the CEO maintains confidence in the twelve billion dollar buy and remains unfazed by the clinical failures.
Coverage (7)
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy BioSpace · 22d ago
- Novartis Raises Guidance Despite Drug-Trial Setbacks Hitting Profit WSJ · 22d ago
- Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal Fierce Pharma · 22d ago
- Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition Financial Times · 22d ago
- Novartis lifts annual profit guidance despite $1.9B hit from del-desiran failure FirstWord Pharma · 22d ago
- Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance Reuters · 22d ago
- Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail Fierce Biotech · 22d ago
Topics
Related trends
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Nike hosts first investor day in 9 years as it tries to rightsize its business
Nike holds its first investor day since 2017, unveiling a 2031 financial framework and Full Stride Ahead strategy to reverse declining sales.
Disney beats fourth-quarter estimates, targets $3 billion in savings through cost-cutting efforts
Disney beat Q4 earnings estimates with $1.77 adjusted EPS on $25.9B revenue and announced a $3B cost-savings target by 2029 alongside a 33% dividend increase.
Diamondback nears $5 billion deal to buy drilling portfolio from Double Eagle, FT says
Diamondback Energy agreed to buy Double Eagle subsidiaries for about 15.56 million shares and $2.15 billion cash, valuing the deal at roughly $5 billion, with closing expected December 21, 2026.
Nvidia bought itself a little breathing room in the Jensen Huang comeback fight
Nvidia secures vital breathing room amid the ongoing Jensen Huang comeback battle according to Business Insider.